Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Design and selection of medicaments that modulate the function and activity of interleukin 13

A technology selected from and equivalent to, applied in the direction of interleukin, drug combination, molecular design, etc., can solve problems such as chemical obstacles of carbohydrate building blocks

Inactive Publication Date: 2011-02-09
格莱坎生物科学股份有限公司
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, very few GAG fragments have been developed for therapeutic use, mainly due to the chemically hindered synthesis of carbohydrate building blocks

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Design and selection of medicaments that modulate the function and activity of interleukin 13
  • Design and selection of medicaments that modulate the function and activity of interleukin 13
  • Design and selection of medicaments that modulate the function and activity of interleukin 13

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0237] Sequence and structure of heparin and heparan sulfate

[0238]The most well-studied and best-understood sequence of heparin monosaccharide residues is the specific pentasaccharide as the minimum condition for high affinity to antithrombin. It is the sequence that accounts for the high anticoagulant potency of heparin and thus its use as an anticoagulant; the basic pentasaccharide has been made synthetically and is itself used as a drug (Petitou and van Boeckel, Angew. Chem. Int. Edit. 43:3118, 2004). When it became clear that heparin, as a model compound for heparan sulfate, was capable of important physiological interactions with other protein classes such as fibroblast growth factor (Mohammadi et al., Curr. Opin. Struct. Biol. 15:506, 2005), antithrombin Examples of binding sequences lead to the search for other equally specific sequences in heparin or heparan sulfate that confer a specific affinity for any given binding partner. The search for high-level specificit...

Embodiment 2

[0241] Drug Development Technology

[0242] Molecular modeling techniques, especially those in which small molecules are docked into their binding sites, are used in the design of new drugs.

[0243] A routine application of theoretical techniques used in new drug design methods is to take a specific protein such as an enzyme and observe the detailed experimental structure of a complex between the protein and its ligand such as a substrate or inhibitor. On the basis of the structural details of IL-13 and its binding site for GAGs, new compounds were proposed. Through molecular modeling, compounds are screened using a technique called docking computation, which studies the many mutual orientations of proteins and ligands to find out how best to accommodate the ligand in the binding site. Compounds with the best affinity for proteins generate theoretical complexes with suitably low interaction energies.

Embodiment 3

[0245] BIAcore screening test

[0246] The optical phenomenon of surface plasmon resonance is used to monitor physical interactions between molecules. Real-time binding of the protein ligand to the immobilized target is monitored by passing a solution of the potential protein ligand (eg, IL-13) over the sensor surface to which the target (eg, heparin) is coupled. Detection is achieved by measuring changes in the refractive index very close to the sensor surface. When the refractive index changes, the angle at which plasmon resonance occurs changes and this change is directly related to the amount of protein interacting with the surface. Use BIAcore 2000 conveniently. It is very sensitive and its microfluidics ensures that only small amounts of material are required.

[0247] Biotinylated heparin was immobilized on the biosensor chip. Biotinylation proceeds with sulfo-NHS-biotin via the amino group or the reducing end modified with ammonia by reductive amination. A solutio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates generally to the field of medicaments in the form of therapeutic molecules including inflammatory modulators and their design and selection. More specifically, the present invention relates to a target site on Interleukin 13 (IL- 13) by which a GAG molecule or polyanionic glycoconjugate or anionic polysaccharide modulates IL-13 activity or function, said target site selected from the list consisting of amino acids located in the AB loops and / or helix D of human IL- 13 or its homolog or derivative, and the use of said IL- 13 target site to design a medicament for modulating physiological processes. Therapeutic and prophylactic compositions comprising the designed medicaments are also contemplated.

Description

[0001] Date of Application [0002] This application is related to and claims priority to Australian Provisional Patent Application No. 2007907059, filed 21 December 2007, the entire contents of which are hereby incorporated by reference. technical field [0003] In general, the present invention relates to the field of therapeutic molecular forms of drugs, including modulators of inflammation, and their design and selection. Therapeutic and prophylactic compositions comprising the drug are also contemplated. Background technique [0004] Details of the author's bibliography of the publications mentioned in this specification are assembled at the end of the description. [0005] The reference to any prior art in this specification is not and should not be considered as an acknowledgment or any form of suggestion that the prior art constitutes part of the general general knowledge of any country. [0006] The design and selection of therapeutic molecules with a high degree ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G06F19/16C07K14/54A61K31/715C40B30/02G06F19/00A61P29/00A61K31/726G06F17/50A61K31/727A61P37/02C07K2/00A61P37/08A61K35/00G16C20/64
CPCA61K31/727G06F19/706G01N33/68G06F19/16A61K31/726C40B30/02A61K31/715G16B35/00G16C20/60G16B15/00G16C20/50A61P11/00A61P11/02A61P11/06A61P29/00A61P35/00A61P37/02A61P37/06A61P37/08A61P43/00Y02A90/10G16C20/64G16B35/20G16B15/30
Inventor D·R·库姆B·马洛伊
Owner 格莱坎生物科学股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com